Studies of associations between various diseases and the ABO blood groups have shown elevated relative risks for some categories of disease. A strong association between salivary gland tumors and blood group A has been reported, but studies are few and have yielded contradictory results. To investigate this association, we conducted an epidemiologic study of salivary gland tumors diagnosed in Jefferson Country, Alabama (United States), 1968-89. All tumors were histologically confirmed. Blood group information was obtained for 200 individuals with salivary gland tumors, and the distribution of ABO and Rh blood type for cases was compared with that of 52,118 healthy blood donors from the same geographic area. The 38.5 percent of salivary gland tumors in cases with blood group A was similar to the 39.0 percent observed for controls (P = 0.95). No differences were observed when benign and malignant tumors were considered separately, nor for any of the major histologic types of tumor. The distribution of Rh factor among cases and controls also did not differ significantly (P = 0.08).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF00051698 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
NISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08).
BMJ Oncol
October 2023
Biostatistics Department, Centre Leon Berard, Lyon, France.
Objective: Salivary gland cancers (SGC) are rare cancers with currently no standard treatment for recurrent/metastatic disease. Based on checkpoint inhibitors benefit in a broad range of tumours, NIvolumab in Salivary gland CArcinoma of the Head and Neck (NISCAHN) evaluated nivolumab efficacy in SGC.
Methods And Analysis: In this phase II single-stage Fleming design, patients with SGC with a progressive disease progression within 6 months prior to entering the study, were divided into ACC (adenoid cytic carcinoma) and non-ACC.
Nivolumab in salivary gland cancers: confronting the challenges of unlocking the therapeutic benefits of immunotherapy for rare diseases.
BMJ Oncol
October 2023
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Cytological features of oncocytic pleomorphic adenoma of the salivary gland: Using the Milan classification system to report 3 patients.
Mol Clin Oncol
March 2025
Department of Pathology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-8686, Japan.
Pleomorphic adenoma (PA) is the most common salivary gland tumour. Pre-operative fine-needle aspiration (FNA) is currently one of the most widely used cytological examination techniques for the diagnosis of salivary gland tumours. Because PA exhibits characteristic cytological features, cytological diagnosis is straightforward in most cases.
View Article and Find Full Text PDFSurgical management of benign tumors of the parotid gland: the advantages of extracapsular dissection compared to traditional surgical techniques.
Front Surg
January 2025
General Surgery III, Department of General Surgery and Medical-Surgical Specialties, University of Catania, AOU Policlinico "G. Rodolico - San Marco", Catania, Italy.
Introduction: Salivary gland tumors represent only 3%-6% of all head and neck neoplasms, and approximately 70% of these tumors are located in the parotid gland. Most of these tumors are found in the more abundant superficial portion of the parotid gland, lateral to the facial nerve (FN). For many years, the location of the facial nerve between the superficial and deep segments of the parotid gland hindered adequate tumor extirpation.
View Article and Find Full Text PDFSurgical non-aggressive approach for the delivery of 4 cm salivary stone from the submandibular gland duct: Avoiding salivary gland removal - A case report.
Int J Surg Case Rep
January 2025
Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Tishreen University Hospital, Tishreen University, Latakia, Syria. Electronic address:
Introduction And Importance: Salivary calculi represent the most common salivary gland disease. It can vary significantly in size, ranging from less than 1 mm to several centimeters. As the size of the stone increases, the surgical approach becomes more complex and the function of the gland may be compromised, potentially necessitating total gland removal.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!